Successful completion of Autoimmune Program with Ginkgo Bioworks
All screening activities for our Autoimmune Disease Program with partner Ginkgo Bioworks (NYSE: DNA) have been completed on schedule.
“Testing, understanding and modifying the microbiome is key to addressing many diseases and improving our health. Microba’s leading technology is driving this health transformation.”
— Professor Ian Frazer, Chair of Medical Advisory Board